Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ASPH | Q12797 | 3/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361760 | 1.00 | KDM4E (0.43) | KDM4EASPHKDM8HCAR2KEAP1 | |
| SCHEMBL19472423 | 0.82 | KDM4E (0.37) | KDM4EASPHKDM8HCAR2KEAP1 | |
| SCHEMBL19472424 | 0.81 | OPRK1 (0.54) | OPRK1 | |
| SCHEMBL29424961 | 0.79 | GABRP (0.39) | KDM4EASPHKDM8HCAR2NAPRT | |
| SCHEMBL1672011 | 0.79 | HCRTR1 (0.45) | KDM4EHCAR2HCRTR1HCRTR2MYC | |
| SCHEMBL30361654 | 0.79 | ALDH1A1 (0.39) | KDM4EASPHKDM8HCAR2HCRTR1 | |
| SCHEMBL19480838 | 0.79 | ALDH1A1 (0.39) | KDM4EASPHKDM8HCAR2HCRTR1 | |
| SCHEMBL17571439 | 0.79 | SCN10A (0.44) | ASPHHCRTR1AGBL2 | |
| SCHEMBL19472426 | 0.77 | HPGD (0.43) | KDM4EOPRK1 | |
| SCHEMBL19472427 | 0.76 | NOTUM (0.40) | KDM4EASPHKDM8KEAP1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997660-B | N- [ (pyrimidinylamino) propyl ] -, N- [ (pyridylamino) propyl ] -and N- [ (pyrazinylamino) propyl ] aryl carboxamides | 勃林格殷格翰国际有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11236072-B2 | N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| EP-3661928-B1 | N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2021-06-16 | — | — | EP | disclosed |
| EP-3442965-B1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-20200231575-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-,N-[PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINOL)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-07-23 | — | — | US | disclosed |
| EP-3442964-B1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| CN-110997660-A | Novel N- [ (pyrimidinylamino) propyl ] -, N- [ (pyridinylamino) propyl ] -and N- [ (pyrazinylamino) propyl ] arylcarboxamides | 勃林格殷格翰国际有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2019025275-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL] - AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-07 | — | — | WO | disclosed |
| US-9884854-B2 | N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884854-B2 | N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| WO-2017178344-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GHBH (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GHBH (DE) | 2017-10-19 | — | — | US | disclosed |
| WO-2017178341-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | HCRTR2, HCRTR1, CNR2 | KDM4E 2364/4885ASPH 973/4885KDM8 1650/4885 |
| US-20200231575-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-,N-[PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINOL)PROPANYL]ARYLCARBOXAMIDES | HCRTR2, HCRTR1, CNR1 | KDM4E 2043/4885ASPH 966/4885KDM8 1227/4885 |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | HCRTR2, HCRTR1, CNR1 | KDM4E 2986/4885ASPH 578/4885KDM8 981/4885 |
| US-11236072-B2 | N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides | HCRTR2, HCRTR1, CNR1 | KDM4E 2339/4885ASPH 1131/4885KDM8 1153/4885 |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | HCRTR2, HCRTR1, CNR1 | KDM4E 2400/4885ASPH 760/4885KDM8 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.